High-sensitivity microsatellite instability assessment for the detection of mismatch repair defects in normal tissue of biallelic germline mismatch repair mutation carriers.


Journal

Journal of medical genetics
ISSN: 1468-6244
Titre abrégé: J Med Genet
Pays: England
ID NLM: 2985087R

Informations de publication

Date de publication:
04 2020
Historique:
received: 07 05 2019
revised: 16 07 2019
accepted: 16 07 2019
pubmed: 9 9 2019
medline: 5 2 2021
entrez: 9 9 2019
Statut: ppublish

Résumé

Lynch syndrome (LS) and constitutional mismatch repair deficiency (CMMRD) are hereditary cancer syndromes associated with mismatch repair (MMR) deficiency. Tumours show microsatellite instability (MSI), also reported at low levels in non-neoplastic tissues. Our aim was to evaluate the performance of high-sensitivity MSI (hs-MSI) assessment for the identification of LS and CMMRD in non-neoplastic tissues. Blood DNA samples from 131 individuals were grouped into three cohorts: baseline (22 controls), training (11 CMMRD, 48 LS and 15 controls) and validation (18 CMMRD and 18 controls). Custom next generation sequencing panel and bioinformatics pipeline were used to detect insertions and deletions in microsatellite markers. An hs-MSI score was calculated representing the percentage of unstable markers. The hs-MSI score was significantly higher in CMMRD blood samples when compared with controls in the training cohort (p<0.001). This finding was confirmed in the validation set, reaching 100% specificity and sensitivity. Higher hs-MSI scores were detected in biallelic The hs-MSI approach is a valuable tool for CMMRD diagnosis, especially in suspected patients harbouring MMR variants of unknown significance or non-detected biallelic germline mutations.

Identifiants

pubmed: 31494577
pii: jmedgenet-2019-106272
doi: 10.1136/jmedgenet-2019-106272
pmc: PMC7146943
doi:

Substances chimiques

DNA-Binding Proteins 0
G-T mismatch-binding protein 0
MSH2 protein, human EC 3.6.1.3
MutS Homolog 2 Protein EC 3.6.1.3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

269-273

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

J Med Genet. 2014 Jun;51(6):355-65
pubmed: 24737826
Nat Genet. 2015 Mar;47(3):257-62
pubmed: 25642631
J Pediatr. 2006 Jun;148(6):837-9
pubmed: 16769400
Nat Rev Cancer. 2015 Mar;15(3):181-94
pubmed: 25673086
J Med Genet. 2019 Feb;56(2):53-62
pubmed: 30415209
Eur J Cancer. 2014 Mar;50(5):987-96
pubmed: 24440087
Clin Chem. 2014 Sep;60(9):1192-9
pubmed: 24987110
Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14508-13
pubmed: 22853953
Hum Mutat. 2013 Jun;34(6):847-52
pubmed: 23483711
Hum Mol Genet. 2005 Jan 15;14(2):235-9
pubmed: 15563510
J Clin Oncol. 2019 Feb 20;37(6):461-470
pubmed: 30608896
J Med Genet. 2014 May;51(5):283-93
pubmed: 24556086
Bioinformatics. 2014 Apr 1;30(7):1015-6
pubmed: 24371154
Hum Mutat. 2010 Mar;31(3):317-24
pubmed: 20052760
Korean J Pediatr. 2016 Jan;59(1):40-2
pubmed: 26893603
PLoS One. 2015 Mar 27;10(3):e0121980
pubmed: 25816162
Hum Mutat. 2019 May;40(5):649-655
pubmed: 30740824
J Med Genet. 2015 May;52(5):348-52
pubmed: 25691505
Gastroenterology. 2015 Oct;149(4):1017-29.e3
pubmed: 26116798
Am J Gastroenterol. 2014 Aug;109(8):1159-79
pubmed: 25070057

Auteurs

Maribel González-Acosta (M)

Hereditary Cancer Program, Catalan Institute of Oncology - ICO, Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge - IDIBELL, Ciber Oncología (CIBERONC) - Instituto de Salud Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.

Fátima Marín (F)

Hereditary Cancer Program, Catalan Institute of Oncology - ICO, Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge - IDIBELL, Ciber Oncología (CIBERONC) - Instituto de Salud Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.

Benjamin Puliafito (B)

Hereditary Cancer Program, Catalan Institute of Oncology - ICO, Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge - IDIBELL, Ciber Oncología (CIBERONC) - Instituto de Salud Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.

Nuria Bonifaci (N)

Hereditary Cancer Program, Catalan Institute of Oncology - ICO, Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge - IDIBELL, Ciber Oncología (CIBERONC) - Instituto de Salud Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.

Anna Fernández (A)

Hereditary Cancer Program, Catalan Institute of Oncology - ICO, Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge - IDIBELL, Ciber Oncología (CIBERONC) - Instituto de Salud Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.

Matilde Navarro (M)

Hereditary Cancer Program, Catalan Institute of Oncology - ICO, Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge - IDIBELL, Ciber Oncología (CIBERONC) - Instituto de Salud Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.

Hector Salvador (H)

Pediatric Oncology Unit, Hospital Sant Joan de Déu, Esplugues, Barcelona, Spain.

Francesc Balaguer (F)

Department of Gastroenterology, Hospital Clínic, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Silvia Iglesias (S)

Hereditary Cancer Program, Catalan Institute of Oncology - ICO, Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge - IDIBELL, Ciber Oncología (CIBERONC) - Instituto de Salud Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.

Angela Velasco (A)

Hereditary Cancer Program, Catalan Institute of Oncology - ICO, Institut d'Investigació Biomèdica de Girona - IDIBGI, Girona, Spain.

Elia Grau Garces (E)

Hereditary Cancer Program, Catalan Institute of Oncology - ICO, Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge - IDIBELL, Ciber Oncología (CIBERONC) - Instituto de Salud Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.

Victor Moreno (V)

Cancer Prevention and Control Program, Catalan Institute of Oncology - ICO, Institut d'Investigació Biomèdica de Bellvitge - IDIBELL, CIBERESP, L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain.

Luis Ignacio Gonzalez-Granado (LI)

Immunodeficiencies Unit, Department of Pediatrics, Doce de Octubre University Hospital, i+12 Research Institute; Complutense University of Madrid, Madrid, Spain.

Pilar Guerra-García (P)

Hematology and Oncology Unit, Department of Pediatrics, Doce de Octubre University Hospital, Madrid, Spain.

Rosa Ayala (R)

Department of Hematology, Doce de Octubre University Hospital, i+12 Research Institute, Madrid, Spain.

Benoît Florkin (B)

University Department of Pediatrics, CHR Citadelle, Liege, Belgium.

Christian Kratz (C)

Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.

Tim Ripperger (T)

Department of Human Genetics, Hannover Medical School, Hannover, Germany.

Thorsten Rosenbaum (T)

Department of Pediatrics, Sana Kliniken Duisburg, Duisburg, Germany.

Danuta Januszkiewicz-Lewandowska (D)

Department of Pediatric Oncology, Hematology and Transplantation, Poznań University of Medical Sciences, Poznań, Poland.

Amedeo A Azizi (AA)

Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.

Iman Ragab (I)

Pediatrics Department, Hematology-Oncology Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Michaela Nathrath (M)

Pediatric Hematology and Oncology, Klinikum Kassel, Kassel, Germany.
Pediatric Oncology Center, Department of Pediatrics, Technische Universität München, Munchen, Germany.

Hans-Jürgen Pander (HJ)

Institut für Klinische Genetik, Olgahospital, Stuttgart, Germany.

Stephan Lobitz (S)

Department of Pediatric Oncology/Pediatric Hematology, Kliniken der Stadt Köln gGmbH, Children's Hospital Amsterdamer Strasse, Koln, Germany.

Manon Suerink (M)

Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.

Karin Dahan (K)

Centre de Génétique Humaine, Institut de Pathologie et de Génétique (IPG), Gosselies, Belgium.

Thomas Imschweiler (T)

Pediatric Oncology, Helios-Klinikum, Krefeld, Germany.

Ugur Demirsoy (U)

Department of Pediatric Oncology, Kocaeli Universitesi, Kocaeli, Turkey.

Joan Brunet (J)

Hereditary Cancer Program, Catalan Institute of Oncology - ICO, Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge - IDIBELL, Ciber Oncología (CIBERONC) - Instituto de Salud Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.
Hereditary Cancer Program, Catalan Institute of Oncology - ICO, Institut d'Investigació Biomèdica de Girona - IDIBGI, Girona, Spain.

Conxi Lázaro (C)

Hereditary Cancer Program, Catalan Institute of Oncology - ICO, Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge - IDIBELL, Ciber Oncología (CIBERONC) - Instituto de Salud Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.

Daniel Rueda (D)

Hereditary Cancer Laboratory, Doce de Octubre University Hospital, i+12 Research Institute, Madrid, Spain.

Katharina Wimmer (K)

Division of Human Genetics, Medical University Innsbruck, Innsbruck, Austria.

Gabriel Capellá (G)

Hereditary Cancer Program, Catalan Institute of Oncology - ICO, Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge - IDIBELL, Ciber Oncología (CIBERONC) - Instituto de Salud Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain gcapella@iconcologia.net mpineda@iconcologia.net.

Marta Pineda (M)

Hereditary Cancer Program, Catalan Institute of Oncology - ICO, Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge - IDIBELL, Ciber Oncología (CIBERONC) - Instituto de Salud Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain gcapella@iconcologia.net mpineda@iconcologia.net.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH